安普拉特泽TM特雷维西奥TM静脉输送系统的安全性和有效性:批准后的研究结果
Sebastien Hascoet1, Alban-Elouen Baruteau2, Zakaria Jalal3
1Hôpital Marie-Lannelongue, Groupe Hospitalier Paris Saint-Joseph, Faculté de Médecine Paris-Saclay, Université Paris-Saclay, Centre Constitutif Réseau Maladies Rares Cardiopathies Congénitales Complexes (M3C), BME Lab, 92350 Le Plessis-Robinson, France.
Archives of cardiovascular diseases
|November 11, 2023
概括
阿姆普拉特泽TM特雷维西奥TM静脉输送系统 (Trevisio DS) 在通过导管关闭心房隔膜缺陷和圆孔的技术上取得了很高的成功,具有出色的安全性.
科学领域:
- 心血管干预 心血管干预
- 医疗器械技术 医疗器械技术
- 遗传性心脏病治疗方法 治疗方法
背景情况:
- 阿姆普拉特泽TM特雷维西奥TM静脉输送系统 (特雷维西奥DS) 专为输送阿姆普拉特泽TM闭塞剂而设计.
- 它的超灵活的尖端有助于在释放之前精确地定位封闭器.
研究的目的:
- 为了评估特雷维西奥DS的安全性和有效性.
- 专注于通过导管关闭卵孔 (PFO) 和心房隔膜缺陷 (ASD).
主要方法:
- 展望性,市场后,单臂,多中心的观察性研究.
- 特雷维西奥DS用于PFO或ASD患者的AmplatzerTM Occluder输送.
- 技术成功被定义为成功部署封闭器;安全追踪到放电或第7天.
主要成果:
- 144名PFO患者和107名ASD患者在22个欧洲地点注册.
- 技术成功率很高:整体98.4% (97.2%的ASD,99.3%的PFO).
- 设备栓塞的一个严重不良事件 (0.4%),与Trevisio DS性能无关.
结论:
- 特雷维西奥DS的技术成功率很高.
- 输送系统在PFO和ASD关闭方面显示出出色的安全性.
相关概念视频
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...


